Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow BSX
Boston Scientific Corporation (BSX) EPS (diluted)
Boston Scientific Corporation's EPS (diluted) for fiscal 2025 was $1.94, up 55.2% from $1.25 in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.47. Over the past ten years it has ranged from −$0.18 (fiscal 2015) to $3.33 (fiscal 2019); the current reading is higher than 91% of that period. EPS (diluted) has risen for 3 consecutive fiscal years. Boston Scientific Corporation ranks 22nd of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.94 | 55.20% |
| FY2024 | $1.25 | 16.82% |
| FY2023 | $1.07 | 137.78% |
| FY2022 | $0.45 | (34.78%) |
| FY2021 | $0.69 | — |
| FY2020 | −$0.12 | — |
| FY2019 | $3.33 | 179.83% |
| FY2018 | $1.19 | 1,387.50% |
| FY2017 | $0.08 | (68.00%) |
| FY2016 | $0.25 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.61 | (32.22%) |
| Mar 2026 | $0.90 | 100.00% |
| Dec 2025 | $0.45 | (11.76%) |
| Sep 2025 | $0.51 | (3.77%) |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| SYK Stryker Corporation compare | $9.65 |
| STE STERIS plc compare | $8.18 |
| GEHC GE HealthCare Technologies Inc. compare | $4.36 |
| MDT Medtronic PLC compare | $4.06 |
| ABT Abbott Laboratories compare | $3.09 |
| DXCM DexCom, Inc. compare | $2.53 |
| BSX Boston Scientific Corporation | $2.47 |
| EW Edwards Lifesciences Corporation compare | $1.74 |
| PHG Koninklijke Philips N.V. compare | $1.36 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BSX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement